Genmab A/S

Major Shareholder Announcement

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

Articles of Association for Genmab A/S

Grant of Warrants to Genmab Employees

Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA